February 5th 2025
The designations follow the FDA acceptance of IND application for ABO-101 to treat PH1, with a phase 1/2 study planned in the first half of 2025.
A Tethered Approach to Type 2 Diabetes Care – Connecting Insulin Regimens with Digital Technology
View More
Surv.AI Says™: What Clinicians and Patients Are Saying About Glucose Management in the Technology Age
View More
Addressing Healthcare Inequities: Tailoring Cancer Screening Plans to Address Inequities in Care
View More
Cases and Conversations™: Applying Best Practices to Prevent Shingles in Your Practice
View More
Using a health literacy approach with childhood obesity
April 29th 2021Becoming overweight at a young age can lead to long-term obesity and represents an important challenge to tackle in childhood. An investigation looks at the impact of a health literacy intervention on reducing overweight children.
How cystic fibrosis can manifest in the gastrointestinal system
February 17th 2020Although the majority of patients with cystic fibrosis (CF) will be managed by specialty care, the primary care provider is often the first line of contact for many routine concerns. When encountering a patient with CF in the primary setting, there are extrapulmonary symptoms that must be considered in patients, which includes gastrointestinal symptoms.
Gastrointestinal manifestations of cystic fibrosis: A primer for pediatricians
February 13th 2020Significant improvements in cystic fibrosis (CF) care have focused primarily on the pulmonary system, but addressing the gastrointestinal complications of CF presents a major opportunity for improvement in disease management.
Probiotics vs placebo against gastroenteritis
February 1st 2019Of 973 preschool-aged children with acute gastroenteritis who visited 1 of 10 geographically diverse pediatric emergency departments (EDs), those who received a 5-day course of Lactobacillus rhamnosus GG, a commonly recommended and used probiotic, did not have better outcomes than those who received placebo, a prospective, randomized trial found.